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and especially about individualized therapy, we could suspect
that the protective effect of vitamin D on the prostate cancer
development is also individual. It may for example result from
the polymorphism of the receptor of this vitamin and activity
of vitamin D-metabolizing enzymes. Conclusion: The
concentration of vitamin D in blood of patients with prostate
cancer is lower than in the blood of patients with benign
prostate hyperplasia. 
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HSV1716 (SEPREHVIR): AN ONCOLYTIC HERPES
VIRUS FOR CANCER THERAPY
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The HSV-1 mutant HSV1716 has deletions in both copies of
the gene encoding the neurovirulence factor ICP34.5.
HSV1716 effectively kills tumor cell lines in vitro and
oncolysis has induced tumor regression and increased survival
times in a wide range of solid tumor xenograft models
including glioma, hepatocellular carcinoma, melanoma,
medulloblastoma, mesothelioma, ovarian carcinoma and
teratocarcinoma supporting translation into clinical studies. In
completed safety studies, direct intratumoral injection of
HSV1716 has been used to treat patients with recurrent
glioma, metastatic melanoma and squamous cell carcinoma of
the head and neck. 
Phase I dose escalation studies of HSV1716 in
pediatric/young adult patients with non-central nervous system
solid tumors ( http://clinicaltrials.gov/ NCT00931931) and in
pediatric patients with refractory or recurrent high grade
gliomas (NCI Protocol #: PBTC-037) and a phase 1/2a study
in malignant pleural mesothelioma (http://clinicaltrials.gov/
NCT01721018) are currently on-going. Regulatory approval
has recently been obtained for a phase I/2a study in
hepatocellular carcinoma. In total 88 patients have received
HSV1716 and the virus is well-tolerated with no spread to
surrounding normal tissue or no shedding in patients. The
selectivity of HSV1716 for replication only in tumour cells
and intimations of efficacy have been demonstrated.
The oncolytic biopotency of HSV1716 can be enhanced via
the incorporation of exogenous genes that generate novel
functionalities or via combination with drugs that target
specific pathways. For example, expression of the Inhibitor of
New Growth 4 protein generates a more efficacious HSV1716
variant with improved replication kinetics and data
demonstrated that HSV1716 and mTOR inhibitors frequently
combined to enhance cancer cell killing.. Therefore, HSV1716
provides a platform with the potential to generate diverse
therapeutic options.
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Glycosylated oleic acid/vitamin D-binding protein, also known
as oleic acid/Gc protein-derived macrophage activating factor
(OA-GcMAF), has proven effective in the immunotherapy of
solid neoplasms and haematological malignancies. The limited
permeability of the blood brain barrier (BBB), however, is an
obstacle to its widespread use in primary brain tumours, as
well as in brain metastases. In order to overcome this
limitation, we developed a procedure involving the use of
focussed ultrasounds that allow selective permeabilisation of
the BBB and targeted delivery of OA-GcMAF. One day before
the procedure, OA-GcMAF is injected in the proximity of
inguinal nodes; it is administered orally as a fermented milk
product and with suppositories or enemas. The following day,
OA-GcMAF is administered by nebulisation. Measurement of
blood pressure variations and assessment of splenic blood flow
after nebulisation are used to determine the individual
response (1). Five minutes after nebulisation, transcranial
ultrasounds are applied through the temporal acoustic window
on the same side where the lesion is located. With proper
setting, the cerebral cortex can be visualised, thus indicating
that the ultrasound waves reach the gray matter (2). The
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ultrasound could then be directed toward the anatomical
regions where the lesion is located. Most regions of the brain
can be accessed through the temporal acoustic window, with
the exception of distal areas of the frontal and occipital lobes.
Focussed ultrasounds are known to transiently increase the
permeability of the BBB (3) and, therefore, allow passage of
OA-GcMAF that is a relatively lipophilic molecule thanks to
the presence of oleic acid. The procedure lasts 5-15 min,
causes no discomfort or side effects and can be repeated
continuously or in cycles. The procedure can be safely
performed before, during or after other anti-neoplastic
treatments.
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A woman was diagnosed with mammary adenocarcinoma in
the right breast in 1985 at the age of 37, followed by
quadrantectomy, lymphadenectomy and irradiation. In 1999, an
adenocarcinoma was diagnosed in the left breast, followed by
ample resection and anti-oestrogen receptor treatment for 6
years. In April 2014, an infiltrating adenocarcinoma was
diagnosed in the right breast that had been operated in 1985.
Pre-operative biopsy showed weak positivity for progesterone
receptor (PgR, <1%) and high positivity for the oncogene
HER2 (>10%, score 2+). With the goal of boosting her
immune system during the 3 weeks preceding surgery,
glycosylated oleic acid/vitamin D-binding protein (OA-
GcMAF) was administered by subcutaneous injections,
nebulisation and with a fermented milk product rich in OA-
GcMAF. No drug was administered in the 3 weeks preceding
surgery, nor had the patient received any treatment for the
previous 8 years. Following right mastectomy, analysis of the
surgical specimen showed no positivity for HER2 expression
(negative, score 0) and significant increase in positivity of PgR,
from <1% to 20%. These results indicate that OA-GcMAF
treatment suppressed oncogene expression and induced
differentiation of cancer cells. Introduction: The healthy
properties of oleic acid (OA) in breast cancer have been known
for centuries (1) and recent evidences suggest that these
properties are amplified by association of OA with proteins
such as α-lactalbumin and lactoferrins. These proteins form
OA-protein complexes that exhibit highly selective anti-tumour
activity in vitro and in vivo (2). We recently demonstrated that
also a serum protein with the capability to bind OA shows
anticancer effects; this is the glycosylated vitamin D-binding
protein also known as Gc-protein-derived macrophage
activating factor or GcMAF (3). This protein binds both OA
and vitamin D and exerts its immune-stimulating and
anticancer effects through cross-talk with the vitamin D
receptor (4). Here we report a clinical observation suggesting
that OA-GcMAF, that is GcMAF-complexed with OA,
suppresses the expression of a major oncogene involved in
human breast cancer that is the human epidermal growth factor
receptor 2 (HER2). Patients and Methods: A woman was
diagnosed with mammary adenocarcinoma in the right breast in
1985 at the age of 37, followed by quadrantectomy,
lymphadenectomy and irradiation. In 1999, an adenocarcinoma
was diagnosed in the left breast, followed by ample resection
and anti-oestrogen receptor treatment for 6 years. In April
2014, an infiltrating adenocarcinoma was diagnosed in the right
breast that had been operated in 1985. With the goal of
boosting her immune system during the 3 weeks elapsing
between biopsy and programmed surgery, OA-GcMAF
(Goleic®, Immuno Biotech Ltd.) was administered by
subcutaneous injections (880 ng) and nebulisation (880 ng) as
indicated in (3). The patient followed a nutritional regime based
on a low carbohydrate, high protein diet (5). To this end, the
patient was provided with food containing only 2%
carbohydrates (Le Gamberi Foods, Forlì, Italy), and with
essential aminoacids (Master Aminoacid Pattern®, dr. reinwald
healthcare gmbh, Schwarzenbruck, Germany) (6). The patient
was also provided with a fermented milk product containing
colostrum and microorganisms known to produce OA-GcMAF
from the Gc-protein present in milk (Bravo Probiotic®, Les
Alpes, Wellington, NZ). No drug was administered or was
programmed in the 3 weeks preceding surgery, nor had the
patient received any treatment for the previous 8 years. The
analyses on HER2 and other gene expression on the biopsy and
surgical specimens were performed by the laboratory of the
University Hospital of Careggi of the Italian Public Health
Service, in Firenze, Italy. Analyses were performed according
to the European standards of quality (UNI EN ISO 9001:2008)
and were examined and countersigned by four different
professionals. The original documents are conserved in the
archives of the Department of Biomedicine of the Careggi
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